1. Information about this Guideline – Oropharyngeal and Hypopharyngeal Carcinoma
1.1 Editors
The German Guideline Program in Oncology (GGPO) of the Association of the Scientific Medical Societies (AWMF), German Cancer Society (DKG), and the German Cancer Aid (DKH).
1.2 Leading Scientific Societies
Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC)
Deutsche Gesellschaft für Radioonkologie (DEGRO)
1.3 Funding of the Guideline
This guideline was funded by the German Cancer Aid as part of the German Guideline Program in Oncology.
1.4 Contact
Office Leitlinienprogramm Onkologie
c/o Deutsche Krebsgesellschaft e. V.
Kuno-Fischer-Straße 8
D-14057 Berlin
leitlinienprogramm@krebsgesellschaft.de
www.leitlinienprogramm-onkologie.de
1.5 How to cite
Leitlinienprogramm-Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnosis, treatment, prevention and aftercare of oropharyngeal and hypopharyngeal carcinoma, Langversion 1.0, 2024, AWMF-Registernummer 017-082OL, https://www.leitlinienprogramm-onkologie.de/leitlinien/oro-und-hypopharynxkarzinom
1.6 Special Comment
The field of medicine is subject to a continuous process of further development, so that all details provided here, and in particular those on diagnostic and therapeutic procedures, can always only represent the state of knowledge at the time when the medical care guideline was printed. The greatest possible care has been taken with regard to the treatment recommendations given and to the choice and dosage of drugs. However, users are requested to check by referring to the patient package inserts and specialist information provided by the manufacturers, and in cases of doubt to consult a specialist. In the general interest of the guideline editors, readers are requested to draw attention to any questionable points or inconsistencies found.
Users themselves remain responsible for all diagnostic and therapeutic applications, medications, and dosages.
Registered trademarks (protected proprietary names) are not specially identified in this guideline. The absence of an indication of this type can therefore not be taken to suggest that such names are unregistered product names.
All parts of this guideline are protected by copyright. Any usage outside of the provisions of copyright law without written permission from the German Guideline Program in Oncology editors is therefore unlawful and liable to prosecution. No part of this work may be reproduced in any form without written permission from the German Guideline Program in Oncology editors. This applies in particular to reproduction, translation, microfilming and storage, usage and exploitation in electronic systems, intranets and the Internet.
1.7 Objectives of the GGPO
The aim of the Association of the Scientific Medical Societies in Germany (AWMF), the German Cancer Society (DKG), and the German Cancer Aid Foundation (Stiftung Deutsche Krebshilfe) in implementing the German Guideline Program in Oncology (GGPO) is to jointly promote and support the development, updating, and use of scientifically based and practicable guidelines in oncology. The program is based on medical and scientific findings established by the specialist societies and the DKG, consensus among medical experts, users and patients, as well as the AMWF's regulations for guideline development. The program receives specialist support and financing from the German Cancer Aid. In order to reflect the current state of medical knowledge and to take account of medical progress, guidelines have to be regularly checked and updated. The use of the AWMF regulations is intended to provide a basis for developing high-quality oncological guidelines in this framework. As guidelines represent an important instrument for quality assurance and quality management in oncology, they are intended to be used in a targeted and sustained way in everyday medical care. Active implementation measures as well as evaluation programs are therefore important components of the support provided by the German Guideline Program in Oncology. The aim of the program is to create professional preconditions, with secure medium-term financing, for the development and provision of high-quality guidelines in Germany. High-quality guidelines of this type not only support structured knowledge transfer but can also be used in the design of health-care structures. Relevant aspects of this include evidence-based guidelines as a basis for establishing and updating disease management programs, and the use of quality indicators derived from guidelines in the context of certification procedures for organ tumour centres.
1.8 Additional Documents relating to this Guideline
- Short version of the guideline
- Patient guideline
- Guideline report on the guideline development process
- Evidence report
This guideline and all additional documents can be accessed via the following web sites.
- German Guideline Program in Oncology (https://www.leitlinienprogramm-onkologie.de/leitlinien/oro-und-hypopharynxkarzinom)
- AWMF (https://register.awmf.org/de/leitlinien/detail/017-082OL)
- Guidelines International Network (www.g-i-n.net)
1.9 Composition of the Guideline Group
1.9.1 Coordination and Reaction
Guideline Coordinators:
Prof. Dr. Andreas Dietz (University of Leipzig Medical Center)
Prof. Dr. Wilfried Budach (Düsseldorf University Hospital)
1.9.2 Arbeitsgruppen
.
Table 1: Arbeitsgruppen
|
Arbeitsgruppe |
Mitglieder der Arbeitsgruppe (AG-Leiter fett markiert) |
|
Core editorial team |
Andreas Dietz, Wilfried Budach, Jochen Heß, Jens Peter Klußmann, Stephan Lang, Susanne Singer, Susanne Wiegand, Orlando Guntinas-Lichius, Thomas Hoffmann, Wilko Weichert, Katherine Taylor, Oliver Bayer, Georg Maschmeyer |
1.9.3 Patient Involvement
The guideline was drawn up with the direct involvement of 2 patient representative organizations.
Mr. Herbert Helmund and Mr. Gunthard Kissinger were involved in the creation of the guideline from the outset as elected representatives and took part in the consensus conferences with their own voting rights.
1.9.4 Methodological Support
By the German Guideline Program in Oncology:
- Dr. Markus Follmann, MPH MSc (DKG, GGPO)
- Dipl.-Soz.Wiss. Thomas Langer (DKG, GGPO)
- Dr. rer. medic. Susanne Blödt, MScPH (AWMF-IMWi)
- Dr. Monika Nothacker, MPH (AWMF-IMWi)
By the scientific staff of the Department of Epidemiology and Health Services Research, Mainz University Medical Center:
- Prof. Dr. Susanne Singer
- Katherine J. Taylor, MSc
- Oliver Bayer, MSc